Guardant Health (GH) announced that the results of the Phase III SERENA-6 trial – sponsored by AstraZeneca (AZN) – demonstrate the clinical value of the Guardant360 CDx test in a circulating tumor DNA-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of radiological disease progression in breast cancer. Study results were presented at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago and were published in The New England Journal of Medicine. Trial showed AstraZeneca’s camizestrant reduced risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation as detected by Guardant360 CDx
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health presented results of largest study on ctDNA in colon cancer
- Guardant Health management to meet with UBS
- Cathie Wood’s ARK Investment buys 237.4K shares of Guardant Health today
- Guardant Health price target raised to $60 from $50 at Piper Sandler
- Guardant Health price target raised to $57 from $52 at Scotiabank